News - GlaxoSmithKline, Anti-virals


Popular Filters

1 to 25 of 40 results

ViiV Healthcare links with Janssen to investigate single-tablet regimen for maintenance treatment of HIV-1

ViiV Healthcare links with Janssen to investigate single-tablet regimen for maintenance treatment of HIV-1


ViiV Healthcare today announced that they have entered into an agreement with Janssen R&D Ireland, a…

Anti-viralsEdurantGlaxoSmithKlineJanssenJohnson & JohnsonLicensingPharmaceuticalResearchTivicayViiV Healthcare

IQWIG finds added benefit in adult patients for VIIV Healthcare’s Tivicay


In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products (AMNOG),…

Anti-viralsGermanyGlaxoSmithKlinePharmaceuticalPricingRegulationTivicayViiV Healthcare

2014 “drugs to watch” as potential blockbusters

2014 “drugs to watch” as potential blockbusters


The Thomson Reuters Intellectual Property & Science business has released its annual forecast of the…

AfrezzaAnoro ElliptaAnti-viralsCyramzaEli LillyGilead SciencesGlaxoSmithKlineidelalisibMannKindMarkets & MarketingOncologyPharmaceuticalRespiratory and PulmonarySovaldi

India/USA trade dispute could impact AIDS treatment programs


The trade dispute over intellectual property rights between the USA and India is set to derail the distribution…

Anti-viralsCiplaGenericsGilead SciencesGlaxoSmithKlineIndiaPatentsPricingUSA

Brazil National Health System coverage of and access to HIV drugs

Brazil National Health System coverage of and access to HIV drugs


Brazil’s National Health System (SUS) currently provides coverage for 22 drugs that are distributed…

AbbVieAnti-viralsAtriplaBrazilEvipleraGilead SciencesGlaxoSmithKlineHealthcareKaletra TabletsMarkets & MarketingPharmaceuticalSouth AmericaTriovirTruvadaViread

Mixed US court decision on ViiV Healthcare’s Epzicom and Trizivir patents


UK pharma giant GlaxoSmithKline and ViiV Healthcare confirmed that the US District Court for the District…

Anti-viralsEpzicomGenericsGlaxoSmithKlineLegalLupinPatentsTeva Pharmaceutical IndustriesTrizivirViiV Healthcare

New agreement with GSK provides new medicines, saves millions for New Zealand

New agreement with GSK provides new medicines, saves millions for New Zealand


A new agreement with the local subsidiary of UK pharma giant GlaxoSmithKline by New Zealand’s Pharmaceutical…

Anti-viralsAsia-PacificGlaxoSmithKlineHealthcareHematologyNew ZealandPharmaceuticalPricingRespiratory and PulmonarySeretideSerevent Diskus

ViiV Healthcare’s Tivicay approved in Canada for HIV


ViiV Healthcare, the HIV/AIDS joint venture set up by UK pharma giant GlaxoSmithKline with US behemoth…

Anti-viralsdolutegravirGlaxoSmithKlineNorth AmericaPfizerPharmaceuticalRegulationShionogiTivicayViiV Healthcare

Janssen gains rights to Ph II hepatitis C candidate from GSK


Janssen Pharmaceuticals has acquired the investigational compound GSK2336805, an NS5a replication complex…

Anti-viralsGlaxoSmithKlineGSK2336805JanssenJohnson & JohnsonLicensingPharmaceutical

AHF sues GSK for failing to provide discounts on HIV/AIDS drugs


The USA-based AIDS Healthcare Foundation (AHF) said yesterday (September 10) that it has filed a law…

Anti-viralsGlaxoSmithKlineLegalNorth AmericaPharmaceuticalPricing

FDA approves new ViiV Healthcare HIV drug


The US Food and Drug Administration yesterday (August 12) approved Tivicay (dolutegravir), a new drug…

Anti-viralsdolutegravirGlaxoSmithKlineNorth AmericaPfizerPharmaceuticalRegulationShionogiTivicayViiV Healthcare

US FDA approves shipment of quadrivalent flu vaccine to health care providers


The US subsidiary of UK pharma giant GlaxoSmithKline (LSE: GSK) says it has received Food and Drug Administration…

Anti-viralsFluarixGlaxoSmithKlineNorth AmericaPharmaceuticalRegulationVaccines

Immunocore in multi-million deal with GlaxoSmithKline on ImmTACs


Oxford, UK-based biotech firm Immunocore, focused on developing novel biological drugs called ImmTACs…


Regulatory updates for Tris Pharma's Karbinal; GSK's four-strain seasonal flu vaccine


US drug delivery specialist Tris Pharma says that the US Food and Drug Administration has approved its…

Anti-viralsEuropeFluarixGlaxoSmithKlineInflusplit TetraKarbinalNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryTris Pharma

GlaxoSmithKline and Abbott to start production in Ukraine


UK pharma giant GlaxoSmithKline (LSE: GSK) and the USA's Abbott (NYSE: ABT) are considering launching…

Anti-viralsAntibiotics and Infectious diseasesEuropeGlaxoSmithKlineIndarPharmaceuticalProductionVaccines

Regulatory updates on GSK's albiglutide, Roche's hep C test, Activartis AV0113


UK pharma giant GlaxoSmithKline plc (LSE: GSK) says it has submitted a Marketing Authorization Application…

ActivartisalbiglutideAnti-viralsAV0113BiotechnologyDiabetesEperzanEuropeGlaxoSmithKlineNorth AmericaOncologyPharmaceuticalRegulationRoche

Clinical updates at ROI meeting on GSK's dolutegravir and Medivir's simeprevir


UK pharma giant GlaxoSmithKline (LSE: GSK) and Japanese drug major Shionogi (TYO: 4507) reported interim…


Briefs: Roche deal with Chiasma; Vasella payout; FDA priority review for dolutegravir


Swiss drug major Roche (ROG: SIX) has entered into an agreement to develop and commercialize privately…

Anti-viralsdolutegravirGlaxoSmithKlineLicensingManagementNovartisOctreotide AcetatePharmaceuticalRare diseasesRegulationRocheViiV Healthcare

Japan's seasonal flu vaccines market analysis


The Japanese influenza vaccine market is valued at around $702 million in 2012, according to a new report…

Anti-viralsAsia-PacificGlaxoSmithKlineMarkets & MarketingPharmaceuticalSanofiVaccines

Flu vaccine innovation needed to protect children, says GlobalData health care expert


The last time the USA confronted a flu season this early, the virus claimed the lives of nearly 50,000…


Sales of antiretroviral agents for HIV will decline slightly over next decade


Major-market sales of antiretroviral (ARV) agents for HIV will decline slightly over the next decade,…

Anti-viralsBiotechnologydolutegravirGenericsGlaxoSmithKlineGlobalMarkets & MarketingPharmaceuticalRegulationViiV Healthcare

ViiV Healthcare's dolutegravir shows promise in hard-to-treat HIV patients


ViiV Healthcare, and HIV/AIDS company jointly owned by GlaxoSmithKline (LSE: GSK), Pfizer (NYSE: PFE)…

Anti-viralsdolutegravirGlaxoSmithKlinePfizerPharmaceuticalResearchShionogiViiV Healthcare

Vertex links with Janssen and GlaxoSmithKline for combo trials with its VX-135 for hepatitis C


US health care giant Johnson & Johnson's (NYSE: JNJ) Janssen Pharmaceuticals unit has entered into a…

Anti-viralsBiotechnologyGlaxoSmithKlineGSK2336805JanssenJohnson & JohnsonPharmaceuticalResearchsimeprevirVertexVX-135

Revised terms for ViiV Healthcare and Shionogi HIV partnership


UK pharma giant GlaxoSmithKline (LSE: GSK) says that Healthcare, its HIV/AIDS joint venture with Pfizer,…

Anti-viralsdolutegravirGlaxoSmithKlineMergers & AcquisitionsPfizerPharmaceuticalShionogiViiV Healthcare

1 to 25 of 40 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top